ClinicalTrials.gg
Active, not recruitingNCT05864248Updated Feb 9, 2026

Feasibility Study SA of the Supira System for HRPCI

An interventional study of Supira System in Heart Diseases, Coronary Artery Disease (CAD) and Heart Failure, sponsored by Supira Medical. Active, not recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Supira Medical · Not applicable, Interventional, and Device feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies in Heart Diseases with a site in Brazil — 11 open to participants now, 13 under way, 3 of them phase 3. Heart Diseases · Brazil.

Enrollment
33rd of 44
71 · median 274
Started
2023
with 4 others
No phase
21 of 48
7 open now
Primary completion
2025-04
later than 2 of 12 live
Registered
38th of 48
by date

Among the 48 studies in Heart Diseases with a site in Brazil, this one is the 33rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 38th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

11 of the 48 studies in Heart Diseases with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 129 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 33 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Diseases with a site in Brazil, or all of them as a file.
02

Study summary

The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).

Read the detailed description

The Feasibility Study SA is a prospective, single-arm, interventional multi-center study enrolling up to 100 treated subjects.

The Supira Catheter is a single-use percutaneous expandable blood pump designed to unload the left ventricle by actively transporting blood from the left ventricle into the aorta.

The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option

03

Conditions studied

  • Heart Diseases
  • Coronary Artery Disease (CAD)
  • Heart Failure

Keywords

  • High-risk percutaneous coronary intervention
  • Peripheral ventricular assist device
  • Supira System
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible, subjects must meet ALL of the following inclusion criteria:

  1. Age ≥ 18 and ≤ 90 years
  2. Will undergo elective or urgent HRPCI, where hemodynamic support is needed, as determined by the institutional Heart Team
  3. Signed the

To be eligible, subjects must NOT meet ANY of the following exclusion criteria:

  1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure. Cardiogenic shock is defined as: systemic hypotension (systolic BP \< 90 mmHg or the need for inotropes/pressors to maintain a systolic BP > 90 mmHg) plus one of the following: any requirement for inotropes/pressors prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion or use of intra-aortic balloon pump (IABP), or any other circulatory support device.
  2. Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
  3. Evidence of left ventricular thrombus
  4. Moderate or greater aortic valvular disease or regurgitation (≥ 2+ on a 4-grade scale as assessed on transthoracic echo cardiogram (TTE)
  5. Moderate or greater aortic stenosis (gradient >20 mmHg or valve area \< 1.5 cm\^2 as assessed on TTE)
  6. Previous aortic valve replacement or reconstruction
  7. Ascending or descending aortic dissection or aortic aneurysm > 4.5 cm
  8. Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the device
  9. Presence of decompensated liver disease; severe liver dysfunction (Child class C)
  10. Patients requiring renal replacement therapy with dialysis
  11. Infection of the proposed procedural access site or systemic active infection requiring ongoing antibiotic therapy
  12. Current or history of heparin-induced thrombocytopenia (HIT)
  13. Known to intravenous contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to heparin, aspirin, ADP receptor inhibitors, or nitinol
  14. Known or suspected coagulopathy or abnormal coagulation parameters (defined as count ≤ 100,000/mm³ or spontaneous ≥ 1.5 or known fibrinogen ≤ 1.5 g/L)
  15. Any condition or scheduled surgery that will require discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
  16. Planned coronary intervention within 30 days post index procedure
  17. Breastfeeding or pregnant
  18. Currently participating in active follow-up phase of another clinical study of an drug or device
  19. Active COVID-related infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  20. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
  21. Considered to be part of a vulnerable population (defined as individuals with mental disability, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    HRPCI patients

    Patients undergoing non-emergent, high-risk percutaneous coronary interventions.

    Device: Supira System

Interventions

  • DeviceSupira System

    The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.

06

What researchers measure

Primary outcomes

  1. Primary Feasibility Endpoint: Successful initiation and maintenance of hemodynamic support without sustained hypotension throughout the index procedure.

    Sustained hypotension is defined as sustained mean arterial pressure (MAP) \< 60mmHg requiring (1) more than one administration of inotropes/vasopressors within 5 minutes, OR (2) continuous infusion of inotropic/pressor medications, OR 3) alternative mechanical circulatory support, to restore hemodynamics.

    Time frame: From device delivery through device removal (up to 4 hours).

  2. Primary Safety Endpoint: Rate of composite major device-related adverse events (MDRAEs), from device delivery through device removal.

    MDRAEs related to the device.

    Time frame: From device delivery through device removal (up to 4 hours).

Secondary outcomes

  1. Rate of Technical Success.

    Completion of the entire Supira System procedure, including delivery, operation without device malfunction, and successful retrieval of the catheter.

    Time frame: From device delivery through device removal (up to 4 hours).

  2. Rate of Procedural Success

    Rate of technical success without procedural serious adverse events (SAEs).

    Time frame: From device delivery through device removal (up to 4 hours).

  3. Rate of composite MDRAEs from device removal through hospital discharge or 72 hours post-procedure, whichever comes first.

    MDRAEs related to the study device.

    Time frame: From device removal through hospital discharge or 72 hours post-procedure, whichever occurs first.

  4. Rate of composite MDRAE from hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.

    Major adverse events related to the study device.

    Time frame: From hospital discharge or 72 hours post-procedure (whichever occurs first)

  5. Rate of composite MDRAE from 30 days to 90 days post device removal (for subjects enrolled and treated after the first 30 subjects).

    Major adverse events related to the device.

    Time frame: From 30 days to 90 days post device removal.

07

Study locations

2 sites
  • Instituto Dante Pazzanese De Cardiologia (Dante)
    São Paulo, 04012-909, Brazil
  • 'Instituto Do Coração de São Paulo (InCor)'
    São Paulo, 5403-000, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 19 months.

Of 73 industry-sponsored interventional studies with no phase under Heart Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 19 months is below that.

Counting every sponsor, half of 336 studies reached it within 25 months; a quarter within 10 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 18, 2023
StartActual
Sep 13, 2023
Primary completionActual
Apr 30, 2025
CompletionEst.
Mar 30, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864248
Lead sponsor
Supira Medical
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Sep 13, 2023
Primary completion
Apr 30, 2025
Completion
Mar 30, 2026 (estimated)
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion